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         ABSTRACT 
INTRODUCTION : Randomized Controlled Trials (RCTs) are considered to 
be the best among all clinical studies for the evaluation of clinical 
interventions. However, much of the medical knowledge comes from 
Observational Studies (OS). The CONSORT ( Consolidated Standards of 
Reporting Trials) statement is a checklist published in 1996, aiming to 
improve the quality of RCTs. The STROBE ( Strengthening the reporting of 
Observational studies in Epidemiology ) statement is published in 2007 to 
improve the quality of OS.  
AIM OF THE STUDY : The aim of this study is to assess published RCTs and 
OS, concerning the use of Paracetamol ( or Acetaminophen ) as an 
alternative therapeutic approach in the treatment of Patent Ductus 
Arteriosus ( PDA ) in preterm neonates. 
METHODS : PubMed was searched for English-language RCTs and OS 
about the use of Paracetamol in the treatment of PDA. All RCTs 
comparing the effectiveness and safety of paracetamol to those of  
indomethacin and ibuprofen which are used as a first choice drug in PDA 
in preterm neonates, or of a placebo, were eligible. They were assessed 
using the 25-item CONSORT checklist of 2010. All OS were eligible and 
they were assessed using the 22-item STROBE checklist of 2007. 
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 RESULTS : The search identified nine eligible articles for RCTs and 22 
eligible articles for OS.  Only 2 of the 9 RCTs had a CONSORT adherence of 
> 75 % and 7 of the 22 OS a STROBE adherence > 75 %. 
CONCLUSIONS : Quality of reporting in RCTs and OS on paracetamol for 
treatment of PDA is unsatisfactory. Further improvement is needed. 
KEY WORDS : CONSORT, Randomized Controlled Trials, STROBE, Observational 
Studies, Quality, Paracetamol, Patent Ductus Arteriosus.  
 
ΠΕΡΙΛΗΨΗ 
ΕΙΣΑΓΩΓΗ : Οι Τυχαιοποιημένες Κλινικές Μελέτες ( ΤΚΜ ) θεωρούνται οι 
καλύτερες κλινικές μελέτες για την αξιολόγηση των κλινικών 
παρεμβάσεων. Όμως μεγάλο μέρος της ιατρικής γνώσης προέρχεται από 
τις μελέτες παρατήρησης ( ΜΠ ). Η δήλωση CONSORT ( Ενισχυμένα 
Πρότυπα Αναφοράς Δοκιμών ) είναι ένας Κατάλογος Στοιχείων  που 
δημοσιεύτηκε το 1996, με σκοπό να βελτιώσει την ποιότητα των ΤΚΜ. Η 
δήλωση STROBE ( Ενδυνάμωση της Αναφοράς στις Μελέτες 
Παρατήρησης στην Επιδημιολογία ) δημοσιεύτηκε το 2007 με σκοπό να 
βελτιώσει τις ΜΠ.  
ΣΤΟΧΟΙ : Σκοπός αυτής της μελέτης είναι να εκτιμήσει την ποιότητα 
αναφοράς των δημοσιευμένων ΤΚΜ και ΜΠ που αφορούν στη χρήση 
παρακεταμόλης ( ή ακεταμινοφαίνης ) ως εναλλακτικής θεραπευτικής 
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προσέγγισης στη θεραπεία του Ανοιχτού Βοταλλείου Πόρου (ΑΒΠ) στα 
πρόωρα νεογνά. 
ΜΕΘΟΔΟΙ : Διερευνήθηκε το PubMed για ΤΚΜ στην αγγλική γλώσσα που 
αφορούσαν στη χρήση της παρακεταμόλης στην θεραπεία του ΑΒΠ. 
Επιλέχτηκαν όλες οι ΤΚΜ που συνέκριναν την αποτελεσματικότητα και 
την ασφάλεια της παρακεταμόλης έναντι εκείνων της ινδομεθακίνης, της 
ιβουπροφένης, ή ενός εικονικού φαρμάκου. Η ποιότητα αναφοράς 
αξιολογήθηκε με βάση τον κατάλογο στοιχείων CONSORT του 2010. 
Επιλέχθηκαν όλες οι ΜΠ και αξιολογήθηκαν με βάση τον κατάλογο 
στοιχείων STROBE του 2007.  
ΑΠΟΤΕΛΕΣΜΑΤΑ : Η έρευνα ανέδειξε 9 άρθρα για ΤΚΜ και 22 για ΜΠ. 
Μόνο 2 από τις 9 ΤΚΜ και 7 από τις 22 ΜΠ παρουσιάζουν βαθμό 
εναρμόνισης > 75 % με τα στοιχεία της λίστας CONSORT και της λίστας 
STROBE αντίστοιχα. 
ΣΥΜΠΕΡΑΣΜΑΤΑ : Η ποιότητα των ΤΚΜ και ΜΠ για την παρακεταμόλη 
στη θεραπεία του ΑΒΠ δεν είναι ικανοποιητική. Απαιτείται περαιτέρω 
βελτίωση. 
ΛΕΞΕΙΣ-ΚΛΕΙΔΙΑ : CONSORT, Τυχαιοποιημένες Κλινικές Μελέτες, STROBE, Μελέτες 
Παρατήρησης, Ποιότητα, Παρακεταμόλη, Ανοιχτός Βοτάλλειος Πόρος 
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INTRODUCTION 
 
A persistent patent ductus arteriosus (PDA) is a common complication of 
prematurity and respiratory distress syndrome (RDS) in preterm 
neonates. Its incidence rate may come up to 64% of infants born at 27 to 
28 weeks’ gestation and 87% of infants born at 24 weeks, at 7 days of 
age.1 The ductus arteriosus is a blood vessel that connects the pulmonary 
artery to the aorta during fetal life so that blood bypasses the non-
functioning fetal lungs. After birth it closes so that non-oxygenated blood 
is driven from pulmonary artery to the lungs and oxygenated blood is 
driven from the aorta to the systemic circulation. In the case that DA 
remains open or re-opens after initially closed after birth, it has significant 
sequences deteriorating the clinical status and affecting the survival rate 
of preterm neonates.2,3 As it becomes hemodynamically significant            
( hsPDA ), a left to right shunting starts through the open ductus and 
despite the ability of the left ventricle to increase its output, blood flow 
distribution to vital organs is altered. The haemodynamic instability 
caused by the shunt has gastrointestinal, cerebral and renal effects 
including necrotizing enterocolitis (NEC), intraventricular haemorrhage 
(IVH), decreased kidney function and bronchopulmonary dysplasia (BPD) 
and if not treated may even lead to death. 
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There are 3 therapeutical approaches for the treatment of hsPDA:  
1.Conservative approach 
2. Pharmacological approach and  
3. Surgical approach. 
 Non-steroid Anti-inflammatory Drugs (NSAIDS) and specifically 
indomethacin and ibuprofen are the first choise drugs implemented in 
the treatment of hsPDA. The reported treatment success is between    
70% - 85 %.4   By inhibiting the cyclo-oxygenase  (COX) component of 
prostaglandin-H2 synthase (PGHS), these two drugs reduce the levels of 
prostaglandins, on which depends the persistency of ductus arteriosus. 
However these drugs may have serious adverse effects like renal failure, 
gastrointestinal perforation and bleeding, peripheral vasoconstriction and 
decreased platelet aggregation.                                                                      
Very recently paracetamol (acetaminophen), an inhibitor of the 
peroxidase component of prostaglandin-H2 synthetase has been 
considered as an alternative drug for the treatment of infants with 
contraindications to NSAIDS.5 In the literature there is evidence that 
paracetamol may be as effective as the previously used drugs with less 
adverse effects.7-15 However, many aspects of paracetamol use for ductal 
closure in preterm neonates, such as efficacy in extremely preterm and 
low birthweight infants, safety profile, optimal dose, route of 
administration and timing of first dose remain unexplored.6 
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Well designed RCTs are the most reliable research method to establish 
the effectiveness of new healthcare interventions, minimizing biased 
results leading to incorrect treatment decisions in health care at all levels. 
It is important for health care providers to be able to assess the quality of 
the methods used in the published RCTs in order to assess their strengths 
and limitations.  
 A group of scientists and editors developed the CONSORT (Consolidated 
Standards of Reporting Trials) statement in order to improve the quality 
of reporting of RCTs. It was first published in 1996 and updated in 2001. 
The CONSORT Statement is an evidence-based minimum set of 
recommendations including a checklist and flow diagram for reporting 
RCTs and is intended to facilitate the complete and transparent reporting 
of trials and aid their critical appraisal and interpretation16. However, the 
CONSORT statement should not be used as a quality appraisal tool but 
rather as a guide for reporting of RCTs17. The objective of CONSORT is to 
provide guidance to authors about how to improve the reporting of their 
trials. Trial reports need be clear, complete, and transparent 
Many leading medical journals and major international editorial groups 
have endorsed the CONSORT statement in order to improve the quality of 
their publications. The introduction of CONSORT within journals is 
associated with improved quality of reports of RCTs.                                 
After an expert meeting in January 2007, the CONSORT statement has 
been further revised and is published as the CONSORT 2010 Statement. 
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The CONSORT statement 2010 will be used in this study to evaluate the 
published RCTs concerning the effectiveness and safety of Paracetamol in 
the treatment of PDA18. 
The STROBE Statement consists of a checklist of 22 items, which relate to 
the title, abstract, introduction, methods, results, and discussion sections 
of articles. The STROBE Statement provides guidance to authors about 
how to improve the reporting of observational studies and facilitates 
critical appraisal and interpretation of studies by reviewers, journal 
editors, and readers. The STROBE statement 2007 will be used in this 
study to evaluate published OS concerning the use of paracetamol for the 
closure of PDA in preterm neonates.22 
 
METHODS 
 
Data sources and search strategies 
 
We searched PubMed for RCTs concerning the use of paracetamol in the 
treatment of PDA in preterm neonates. We used as filter the 
“Randomized Controlled Trial” type of article and we set no time 
limitation. We used as a search criterion the words Paracetamol or 
Acetaminophen ( synonymes ) and Patent Ductus Arteriosus. Because of 
the small number of RCTs retrieved (N = 9 ) we removed the filter 
“Randomized Controlled Trial”, repeated the search and all articles found 
were also reviewed. All observational studies retrieved ( N = 22 ) were  
included in a separate quality of reporting assessment study. Finally we 
searched the references of the articles retrieved.  
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Selection criteria 
 
We included RCTs in which paracetamol was compared to placebo or  
other drugs used for closure of PDA ( indomethacin, ibuprofen ) 
irrespective of dose, duration and mode of administration in preterm 
infants. Trials were eligible if they had randomly assigned participants to 
two or three treatment arms since paracetamol may be compared to 
indomethacin, ibuprofen or both, or to placebo. In the included studies 
paracetamol has been used either prophylactically or therapeutically.  
For the observational studies the use of paracetamol for closure of  a 
patent ductus arteriosus in preterm infants was the selection criterion 
irrespective of dose, duration and mode of administration.  
 
Reporting assessment tool      
                                     
The CONSORT statement 2010 was the tool of evaluation of the reporting 
quality of the trials. The CONSORT 2010 checklist includes 25 main 
categories and 12 subcategories organized in sections: Title and abstract, 
Introduction, Methods, Results, Discussion and Other information.              
( Figure 1 )   We calculated the percentage of compliance to the CONSORT 
checklist items taking into account the total 37 items. The CONSORT 
explanation and elaboration document was used as a guideline for the 
assessment.18  
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FIGURE 1 : CONSORT 2010 checklist of information to include when 
reporting a randomised trial 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page 
No 
Title and abstract 
 1a Identification as a randomised trial in the title  
1b Structured summary of trial design, methods, results, and 
conclusions (for specific guidance see CONSORT for abstracts) 
 
Introduction 
Background 
and objectives 
2a Scientific background and explanation of rationale  
2b Specific objectives or hypotheses  
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) 
including allocation ratio 
 
3b Important changes to methods after trial commencement 
(such as eligibility criteria), with reasons 
 
Participants 4a Eligibility criteria for participants  
4b Settings and locations where the data were collected  
Interventions 5 The interventions for each group with sufficient details to 
allow replication, including how and when they were actually 
administered 
 
Outcomes 6a Completely defined pre-specified primary and secondary 
outcome measures, including how and when they were 
assessed 
 
6b Any changes to trial outcomes after the trial commenced, 
with reasons 
 
Sample size 7a How sample size was determined  
7b When applicable, explanation of any interim analyses and 
stopping guidelines 
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Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence  
8b Type of randomisation; details of any restriction (such as 
blocking and block size) 
 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until 
interventions were assigned 
 
 
Implementation 
10 Who generated the random allocation sequence, who 
enrolled participants, and who assigned participants to 
interventions 
 
Blinding 11a If done, who was blinded after assignment to interventions 
(for example, participants, care providers, those assessing 
outcomes) and how 
 
11b If relevant, description of the similarity of interventions  
Statistical 
methods 
12a Statistical methods used to compare groups for primary and 
secondary outcomes 
 
12b Methods for additional analyses, such as subgroup 
analyses and adjusted analyses 
 
Results 
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of participants who were 
randomly assigned, received intended treatment, and were 
analysed for the primary outcome 
 
13b For each group, losses and exclusions after randomisation, 
together with reasons 
 
Recruitment 14a Dates defining the periods of recruitment and follow-up  
14b Why the trial ended or was stopped  
Baseline data 15 A table showing baseline demographic and clinical 
characteristics for each group 
 
Numbers 
analysed 
16 For each group, number of participants (denominator) 
included in each analysis and whether the analysis was by 
original assigned groups 
 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each 
group, and the estimated effect size and its precision (such 
as 95% confidence interval) 
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17b For binary outcomes, presentation of both absolute and 
relative effect sizes is recommended 
 
Ancillary 
analyses 
18 Results of any other analyses performed, including 
subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
 
Harms 19 All important harms or unintended effects in each group (for 
specific guidance see CONSORT for harms) 
 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses 
 
Generalisability 21 Generalisability (external validity, applicability) of the trial 
findings 
 
Interpretation 22 Interpretation consistent with results, balancing benefits and 
harms, and considering other relevant evidence 
 
Other information 
 
Registration 23 Registration number and name of trial registry  
Protocol 24 Where the full trial protocol can be accessed, if available  
Funding 25 Sources of funding and other support (such as supply of 
drugs), role of funders 
 
  
 
 
 
 
 
 
 
For the observational studies the STROBE ( Strengthening the Reporting 
of Observational Studies in Epidemiology ) statement checklist was used 
for the assessment of the studies22.( Figure 2 ) 
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FIGURE 2 : STROBE Statement—checklist of items that should be included 
in reports of observational studies 
 
 
Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in 
the title or the abstract 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data collection 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources 
and methods of selection of participants. Describe methods of 
follow-up 
Case-control study—Give the eligibility criteria, and the sources 
and methods of case ascertainment and control selection. Give 
the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants 
(b) Cohort study—For matched studies, give matching criteria 
and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria 
and the number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
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Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability 
of assessment methods if there is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. 
If applicable, describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
(b) Describe any methods used to examine subgroups and 
interactions 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up 
was addressed 
Case-control study—If applicable, explain how matching of cases 
and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods 
taking account of sampling strategy 
(e) Describe any sensitivity analyses 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of 
interest 
(c) Cohort study—Summarise follow-up time (eg, average and total 
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amount) 
Outcome data 15* Cohort study—Report numbers of outcome events or summary 
measures over time 
Case-control study—Report numbers in each exposure category, or 
summary measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary 
measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
(b) Report category boundaries when continuous variables were 
categorized 
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, 
and sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any 
potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and 
other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 
article is based 
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RESULTS  
 
Nine studies were included in the CONSORT study that reported on the 
whole on one thousand and four infants (1004). One study compared 
paracetamol to both ibuprofen and indomethacin12. Six studies compared 
treatment of PDA with paracetamol versus ibuprofen 7,8,11,13-15  enrolling 
579 infants. One study compared paracetamol to indomethacin9 and one 
to placebo10. One more RCT was found (author Asbagh,2015), not in the 
PubMed search but in the Cochrane Collaboration Review article about 
the use of paracetamol for PDA in preterm or low birth weight infants 
published in 2018 19  but, the abstract excluded, the article was written in 
the Farci language and no detailed data could be extracted. Two more 
studies were excluded20,21  since they were protocols. 
Twenty-two studies were included in the STROBE study that reported on 
a total population of four hundred thirty-seven preterm neonates (437). 
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         FIGURE 3 PUBMED SEARCH FLOW DIAGRAM  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical characteristics, treatment protocols and publication details of the 
RCTs are gathered in table 1.  
 
 
ARTICLES FOUND 
IN PUBMED 
 N= 54 
 
 
 
ARTICLES EXCLUDED 
 13 REVIEWS 
 2 COHRANE 
SYSTEMATIC 
REVIEWS 
 1 META-ANALYSIS 
 1 SYSTEMATIC 
REVIEW AND 
META-ANALYSIS 
 22 OBSERVATIONAL  
 3 PROTOCOLS 
 4 IRRELATIVE 
 1 CASE REPORT 
 
RCTS FOR 
ASSESSMENT 
             N = 9 OBSERVATIONAL 
STUDIES 
N=22 
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TABLE 1 : Characteristics of the RCTs  
 
Author 
Publication year 
Sample 
size 
Birth Weight 
 g 
Gestational 
age 
weeks 
Route 
Dose 
mg/kg/day 
1 
Dang et al  
PLoS One, 20137 
Paracetamol 
N=80 
1591±348 31.2 ± 1.8 
ORAL 
60 mg/kg x 3days 
Ibuprofen N=80 1531±453 30.9 ± 2.2 
10mg/5mg/5mg 
/kg/day 
2 
Oncel  et al 
J Pediatr, 20148 
Paracetamol 
N=45 
931±217 27.3 ± 1.7 
ORAL 
60 mg/kg x 3days 
Ibuprofen   
N=45 
973±224 27.3 ± 2.1 
10mg/5mg/5mg 
/kg/day 
3 
Dash et al 
Indian Pediatr, 
20159 
Paracetamol 
N=38 
989±299 28.5±2.7 ORAL 60 mg/kg x7 days 
Indomethacin 
N=39 
1027±262 28.9±2.6 IV 
0.2mg/kg    x3 
days 
4 
Harkin et al  
J Pediatr, 201610 
Paracetamol 
N=23 
1220±430 28.4±2.4 
IV 
Loading dose 
20mg/kg, 30 
mg/kg x 4 days 
Placebo  (0.45% 
saline solution) 
N=25 
1120±340 28.3±2.1  
5 
Bagheri et al  
Iran J Pediatr, 
201611 
Acetaminophen 
N=80 
1646.26±59.14 31.53±2.31 
ORAL 
60 mg/kg x 3days 
Ibuprofen 
N=80 
1642.62±58.46 31.7±2.24 
20mg/10mg/10mg 
/kg/day 
6 
El-Mashad  
Eur J Pediatr, 
201612 
Paracetamol 
N=100 
1100±130 26±1.9 
IV 
60 mg/kg x 3days 
Ibuprofen 
N=100 
1000±120 25±2.1 
10mg/5mg/5mg 
/kg/day 
Indomethacin 
N=100 
1100±140 26±2.1 0.2mg/kg/12hx3 
7 
Yang et al  
Exp Ther med, 
201613 
Acetaminophen 
N=44 
2219±606 33.6±2.1 
ORAL 
60 mg/kg x 3days 
 
Ibuprofen  
N=43 
2091±657 33.4±2.1 
10mg/5mg/5mg 
/kg/day 
8 
Al-lawama et al 
J Int Med Res, 
201814 
Paracetamol 
N=13 
1059±386 28 (23-32) 
ORAL 
40 mg/kg x 3days 
 
Ibuprofen  
N=9 
1192±269 28 (25-35) 
10mg/10mg/10mg 
/kg/day 
9 
El-Farrash 
J Matern Fetal 
Neonatal Med, 
201815 
Paracetamol 
N=30 
1530±560 30.53±1.55 
ORAL 
60 mg/kg x 3days 
 
Ibuprofen  
N=30 
1740±470 31.73±1.98 
10mg/5mg/5mg 
/kg/day 
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Table 2 :  Percentage of CONSORT items reported in the article 
STUDY 
Articles by 
author 
CONSORT ITEMS 
REPORTED 
Percentage of 
CONSORT items 
reported 
1 
Dang et al, 
20137 
26/37 70 % 
2 
Oncel et al, 
20148 
25/37 68 % 
3 
Dash et al, 
20159 
28/37 76 % 
4 
Harkin et al, 
201610 
30/37 81 % 
5 
Bagheri et al, 
201611 
21/37 57 % 
6 
El-Mashad et  al, 
201612 
23/37 62 % 
7 
Yang et al, 
201613 
19/20 51 % 
8 
Al-lawama et al, 
201814 
23/37 62 % 
9 
El-Farrash et al, 
201815 
25/37 68 % 
 
2 articles had a CONSORT compliance score of > 75 %  ( 22.2 % ). 
5 articles had a CONSORT compliance score > 65 %  ( 55.5 % ). 
7 articles had a CONSORT compliance score > 60 % ( 77.7  % ). 
9 articles had a CONSORT compliance score > 50 %  ( 100 % ). 
 
Studies were published in eight different journals. The impact factors of 
the journals in comparison with the CONSORT compliance score of the 
articles published are reported in table 2. 
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TABLE 3 Impact factors of Journals where the articles were published 
JOURNAL NAME ARTICLES IMPACT 
FACTOR 
CONSORT 
SCORE 
JOURNAL OF PEDIATRICS  2 
4 
3.667 
70% 
84% 
PLOS ONE 1 2.766 73% 
EUROPEAN JOURNAL OF 
PEDIATRICS 
6 2.242 54% 
THE JOURNAL OF MATERNAL 
FETAL AND NEONATAL 
MEDICINE 
9 1.493 65% 
EXPERIMENTAL AND 
THERAPEUTIC MEDICINE 
7 1.41 51% 
INDIAN PEDIATRICS 3 1.145 76% 
JOURNAL OF INTERNATIONAL 
MEDICAL RESEARCH 
8 1.023 60% 
IRANIAN JOURNAL OF 
PEDIATRICS 
5 0.902 57% 
 
Apart from the total compliance score of each article, it is of interest to 
analyze the frequency of reporting of the 37 items of the CONSORT 
checklist for the nine articles combined. As all articles were published 
recently( after 2013 ), no pre- and post- CONSORT statement compliance 
difference could be investigated. 
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The results of this analysis are depicted in table 4 : 
 
TABLE 4 
Section/Topic Item No Number of 
articles 
reporting the 
item 
Percentage of 
articles reporting 
the CONSORT 
item  
Title and abstract 1a 6/9 67 % 
 1b 7/9 78 % 
Introduction    
Background and  
objectives 
2a 9/9 100 % 
2b 9/9 100 % 
Methods    
Trial design 3a 6/9 67 % 
3b 0/9 0 % 
Participants 4a 9/9 100 % 
4b 9/9 100 % 
Interventions 5 9/9 100 % 
Outcomes 6a 9/9 100 % 
6b 0/9 0 % 
Sample size 7a 9/9 100 % 
7b 0/9 0 % 
Randomization:    
Sequence  
  generation 
8a 6/9 67 % 
8b 5/9 55 % 
Allocation 
  concealment   
  mechanism 
9 8/9 89 % 
Implementation 10 1/9 11 % 
Blinding 11a 7/9 78 % 
11b 1/9 11 % 
Statistical  
methods 
12a 9/9 100 % 
12b 3/9 33 % 
Results    
Participant flow 
A diagram is 
recommended 
13a 7/9 78 % 
13b 7/9 78 % 
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Recruitment  14a 9/9 100 % 
14b 0/9 0 % 
Baseline data 15 9/9 100 % 
Numbers analysed 16 8/9 89 % 
Outcomes and 
estimation 
17a 5/9 55 % 
17b 2/9 22 % 
Ancillary analyses 18 5/9 33 % 
Harms 19 9/9 100 % 
Discussion    
Limitations 20 9/9 100 % 
Generalisability 21 8/9 89 % 
Interpretation 22 9/9 100 % 
Other information    
Registration 23 6/9 67 % 
Protocol 24 1/9 11 % 
Funding 25 4/9 44 % 
 
From the analysis by CONSORT item it is noted that only 20 out of the 37 
items ( 54 % ) are addressed in 75 % or more of the articles published 
from 2013-2018. Items addressed in 100 % of the articles were 
background and objectives ( 2a, 2b ), participants ( 4a, 4b ), interventions 
( 5 ), outcomes   ( 6a ), sample size (7a ), statistical methods (12a ), 
recruitment ( 14a ), baseline data (15 ), harms (19 ), limitations ( 20 ) and 
interpretation ( 22 ).  
Implemenation ( 10 ), additional analyses ( 12b ), outcomes and 
estimation (17a, 17b ), ancillary analyses (18 ) and protocol ( 24 ) were 
the most underreported items. 
Clinical characteristics, treatment protocols and publication details of the 
Observational studies are gathered in table 5.              
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TABLE 5 : Characteristics of Observational studies 
 
Author 
Publication year 
Sample 
size 
Birth Weight 
Median    
(min-max), g 
Gestational 
age 
Median               
(min-max), 
days 
Postnatal 
age 
Median           
(min-max), 
days 
Route 
Dose 
mg/kg/day 
1 
Hammerman et al 
Pediatrics,20115 
5 
935 
(720-1210) 
26 
(26-29 ) 
10 
(3-35) 
ORAL 60 
2 
Oncel et al 
Arch Dis 
Child Fetal Neonatal 
Ed.,  201223 
8 
995 
(630-2970) 
28 
(23-26) 
9.5 
(5-27) 
ORAL 60 
3 
Oncel et al 
Neonatology, 201324 
10 
775 
(590-990) 
27 
(24-29) 
6 
(2-15) 
IV 60 
4 
Alan et al 
Neonatology, 201325 
3 
840 
(810-1240) 
26 
(26-33) 
9 
(8-19) 
IV 60 
5 
Yurttutan et al 
J Matern Fetal 
Neonatal  Med, 
201326 
6 
1260 
(920-1600) 
28 
(26-32) 
4 
(3-7) 
ORAL 60 
6 
Sinha et al 
J Clin Neonatol, 
201327 
10 
995 
(800-1380) 
29 
(27-33) 
5 
(4-7) 
ORAL 45 
7 
Jasani et al  
J Postgrad Med, 
201328 
6 
1107 
(1040-1234) 
29 
(28-31) 
5.5 
(3-10) 
ORAL 60 
8 
Kessel et al 
J Matern Fetal 
Neonatal Med, 
201429 
 
7 
991 
(789-1322) 
28 
(26-30) 
6 
(2-27) 
ORAL 60 
9 
Nadir et al 
J Perinatol, 201430 
 
7 
853 
(656-951) 
26 
(24-27) 
5 
(2-22) 
ORAL 60 
10 
El Khuffash 
Pediatr Res, 201431 
( Human study ) 
21 
790 
(530-1200) 
25 
(24-28) 
25 
(3-56) 
9 IV 
12 
ORAL 
60 
11 
Aikio et al 
J Matern Fetal 
Neonatal  Med, 
201432 
102 1201±379 28.5±1.9 
8 
(3-19.5) 
IV 
LOADING 
20 
30 
88 
 
1308±369 
 
29±2.1   
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12 
Tekgunduz et al 
Cardiol Young, 
201433 
 
13 
950 
(470-1390) 
29 
(24-31) 
3 
(2-9) 
IV 
30             
(1st patient 
60) 
13 
Ozdemir et al 
Pediatr Cardiol, 
201434 
 
7 
820 
(620-1615) 
25 
(23-32) 
35 
(20-47) 
ORAL 60 
14 
Terrin et al  
Ital  J Pediatr, 201435  
 
8 
700 
(530-930) 
26 
(23-29) 
2 
(2-5) 
IV 30-60 
15 
El Khuffash 
Arch Dis Child Fetal 
Neonatal Ed, 201536 
 
36 
773 
(645-954) 
26 
(24-27) 
27 
(16-39) 
IV 60 
16 
Roofthooft et al 
Eur J Pediatr, 201537 
 
33 
750 
(365-1130) 
25 
(23-26) 
14 
(IQR=12) 
IV 60 
17 
Weisz et al 
J Perinatol,201638 
 
26 
700 
(633-910) 
24.4 
(24.3-26) 
25 
(18-32) 
ORAL 60 
18 
Memisoglou et al 
J Matern Fetal 
Neonatal Med, 
201639 
11 
790 
(415-1580) 
26 
(23-30) 
3 
(1-15) 
IV 60 
19 
Valerio et al 
Eur J Pediatr,  
201640 
first-
line 
 
30 
853.3±286.
9 
26.3±2.4 
84 h 
(48-360) 
IV 60 
rescue 
18 
 
887.7±297 26.5±2.3 
348 h 
(120-8064) 
20 
Luecke et al 
J Pediatr Pharmacol 
Ther, 201741 
 
 
41 
760 
(614-948) 
25 
(24-27) 
15 
(8-19) 
88% IV 
60 
12% 
ORAL 
21 
Pharande et al  
Pediatr Cardiol, 
201842 
 
20 724.1±143 25.7±1.5 33.5±15 ORAL 60 
22 
Tofe et al 
Front Pediatr, 201843 
9 
1052 
(560-1860) 
28 
(25-32) 
4 
(2-35) 
IV 60 
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TABLE 6 : Number of items of STROBE checklist reported and Percentage of STROBE  
items reported in the article 
 
STUDY 
ARTICLES BY AUTHOR, 
YEAR OF PUBLICATION 
STROBE ITEMS 
REPORTED 
PERCENTAGE 
1 Hammerman et al, 20115 10/23 43.5 % 
2 Oncel et al,  201223 8/23 35 % 
3 Oncel et aL, 201324 17/23 74 % 
4 Alan et al, 201325 6/23 26 % 
5 Yurttutan et al, 201326 12/23 52 % 
6 Sinha et al, 201327 8/23 35 % 
7 Jasani et al , 201328 10/23 43.5 % 
8 Kessel et al, 201429 10/23 43.5 % 
9 Nadir et al, 201430 10/23 43.5 % 
10 El Khuffash et al, 201431 17/23 74 % 
11 Aikio et al, 201432 18/23 78 % 
12 Tekgunduz et al, 201433 15/23 65 % 
13 Ozdemir et al, 201434 15/23 65 % 
14 Terrin et al, 201435 17/23 74 % 
15  El Khuffash et al, 201536 19/23 82.5 % 
16 Roofthooft et al, 201537 20/23 87 % 
17 Weisz et al,201638 19/23 82.5 % 
18 Memisoglou et al, 201639 17/23 74 % 
19 Valerio et al, 201640 20/23  87 % 
20 Luecke et al, 201741 19/23 82.5 % 
21 Pharande et al, 201842 20/23 87 % 
22 Tofe et al, 201843 13/23 56 % 
 
 
7 articles had a STROBE compliance score > 75 % ( 32 % ). 
13 articles had a STROBE compliance score >60 % ( 59 % ). 
15 articles had a STROBE compliance score >50 % ( 68 % ). 
7 articles had a STROBE compliance score < 50 % ( 32 % ). 
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The frequency of reporting of each STROBE checklist item in the 22 
articles combined, as an absolute number and as a percentage, is 
depicted in table 7. 
TABLE 7  
Section/Topic Item No Number of 
articles reporting 
the item 
Percentage 
(%) 
Title and Abstract    
Study design 1a 13/22 59 
Informative summary 1b 18/22 82 
Introduction    
Background/Rationale 2 20/22 91 
Objectives 3 19/22 86 
Methods    
Study design 4 16/22 73 
Setting 5 12/22 54.5 
Participants 6 22/22 100 
Variables 7 16/22 73 
Data sources / 
Measurements 
8 13/22 59 
Bias 9 1/22 4.5 
Study size 10 15/22 68 
Quantative variables 11 4/22 18 
Statistical methods 12 12/22 54.5 
Participants 13 22/22 100 
Descriptive data 14 21/22 95.5 
Outcome data 15 22/22 100 
Main results 16 1/22 4.5 
Other analyses 17 7/22 32 
Discussion    
Key results 18 22/22 100 
Limitations 19 14/22 64 
Interpretation 20 18/22 82 
Generalisability 21 10/22 45.5 
Other information    
Funding 22 10/22 45.5 
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Only 9 of the 23 STROBE items ( 35 % ) were addressed in 75 % or more of 
the articles published between 2011 and 2018 : Informative summary         
( 1b ), background/rationale (2), objectives ( 3 ), participants ( 6 ), 
participants ( 13 ), descriptive data ( 14 ), outcome data ( 15 ), key results 
( 18 ) and interpretation ( 20 ). Bias ( 9 ), quantative variables ( 11 ), main 
results ( 16 ) and other analyses ( 17 ) were the most underreported 
items.  
The articles were published in fourteen different journals.  The impact 
factors of the journals in comparison with the STROBE compliance score 
of the articles published are reported in table 8. 
 
TABLE 8 : Impact factors of Journals where the articles were published 
JOURNAL ARTICLES IMPACT 
FACTOR 
STROBE 
SCORE 
PEDIATRICS 1 5.297 43.5 
ARCHIVES OF DISEASE OF 
CHILDHOOD : FETAL AND 
NEONATAL EDITION 
2 
 
15 
3.953 35 
 
82.5 
PEDIATRIC RESEARCH 10 3.123 74 
NEONATOLOGY 3 
4 
2.688 74 
26 
FRONTIERS IN PEDIATRICS 22 2.335 56 
EUROPEAN JOURNAL OF 
PEDIATRICS 
16 
19 
2.242 87 
87 
JOURNAL OF 
PERINATOLOGY 
9 
17 
2.183 43.5 
82.5 
ITALIAN JOURNAL OF 
PEDIATRICS 
14 1.776 74 
JOURNAL OF MATERNAL 5 1.493 52 
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FETAL AND NEONATAL 
MEDICINE 
8 
11 
18 
43.5 
78 
74 
JOURNAL OF CLINICAL 
NEONATOLOGY 
6  35 
PEDIATRIC CARDIOLOGY 13 
21 
1.54 65 
87 
JOURNAL OF 
POSTGRADUATE 
MEDICINE 
7 1.095 43.5 
CARDIOLOGY IN THE 
YOUNG 
12 0.978 65 
JOURNAL OF PEDIATRIC 
PHARMACOLOGY AND 
THERAPEUTICS 
20  82.5 
 
 
CONCLUSIONS 
The use of paracetamol was introduced only recently in the management 
of the patent ductus arteriosus in preterm infants. The published RCTs 
and Observational studies concerning its effectiveness and safety 
compared to those of NSAIDs, used for the last 4 decades in the 
treatment of PDA, are limited. Their quality, as assessed using the 
CONSORT statement and the STROBE statement respectively, is rated as 
moderate. This is in contrast with the fact that they are published years 
after the publication of the CONSORT and STROBE statements. Essential 
medical and statistical information is well reported, whereas more 
sophisticated methodological issues ( like bias, blinding, additional 
analyses ) are rarely  described. The impact factor of the Journals they are 
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published in, is low : < 4 for RCTs and < 6 for the Observational studies. 
Due to the small number of studies, the short period of existing 
publications and the generally low impact factor of the journals, no  
differencess between separate groups could be investigated. Yet, there is 
a trend for improvement in the STROBE adherence over time for the 
Observational studies.  
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